Eruptive xanthomas secondary to severe hypertriglyceridemia

Article Sidebar

Global Journal of Medical and Clinical Case Reports volume8-issue3 articles
PDF HTML
Submitted: September 29, 2021
Published: Oct 18, 2021
DOI: 10.17352/2455-5282.000142
Keywords:
Hypertriglyceridemia, Xanthoma, Hyperlipidemia, Lipid-reducing therapy, Statins

Main Article Content

Wade Hopper
Edward via College of Osteopathic Medicine, 350 Howard St, Spartanburg, SC, 29307, USA
Spiro Veria
University of Toledo College of Medicine and Life Sciences, 3000 Arlington Ave, Toledo, OH, 43614, USA
Logan Glosser*
University of Toledo College of Medicine and Life Sciences, 3000 Arlington Ave, Toledo, OH, 43614, USA
Anu Garg
Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, 43614, USA
Mohammed T Awad
Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, 43614, USA
Justin Smith
University of Toledo College of Medicine and Life Sciences, 3000 Arlington Ave, Toledo, OH, 43614, USA
Shahab Ud Din
Department of Internal Medicine, University of Toledo Medical Center, Toledo, OH, 43614, USA

Abstract

Xanthomas are benign cutaneous manifestations of extracellular lipid accumulation. Eruptive xanthoma is characterized by the acute, widespread presentation of a papular rash and usually involves the back, buttocks, and extremities. Eruptive xanthoma is associated with hyperlipidemia, hypertriglyceridemia, and an increased long-term risk of atherosclerotic cardiovascular disease. We present a case of eruptive xanthoma accompanied by severe hypertriglyceridemia (10,164 mg/dL) in which the course of the disease was reversed following implementation of lipid-lowering pharmacotherapy.

Downloads

Download data is not yet available.

Article Details

Hopper, W., Veria, S., Glosser, L., Garg, A., Awad, M. T., Smith, J., & Din, S. U. (2021). Eruptive xanthomas secondary to severe hypertriglyceridemia. Global Journal of Medical and Clinical Case Reports, 8(3), 112–115. https://doi.org/10.17352/2455-5282.000142
Case Reports

Copyright (c) 2021 Hopper W, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Zak A, Zeman M, Slaby A, Vecka M (2014) Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158: 181-188. Link: https://bit.ly/3DS5Iv4

Roga G, Jithendriya M (2016) Eruptive xanthoma: Warning sign of systemic disease. Cleve Clin J Med 83: 715-716. Link: https://bit.ly/3jdJCvn

Martínez DP, Díaz JO, Bobes CM (2008) Eruptive xanthomas and acute pancreatitis in a patient with hypertriglyceridemia. Int Arch Med 1: 6. Link: https://bit.ly/3FSE6YG

Duzayak S, Sayiner ZA, Erkılıç S, Inaloz HS (2017) Acute pancreatitis with eruptive xanthoma. BMJ Case Rep 2017: bcr2017221543. Link: https://bit.ly/3FY51Cw

Scherer J, Singh VP, Pitchumoni CS, Yadav D (2014) Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol 48: 195-203. Link: https://bit.ly/3j9WAKq

Santiago L, Pinho A, Cardoso JC (2018) Eruptive Xanthomas: A Cardinal Manifestation of Serious Metabolic Disease. Acta Med Port 31: 219-222. Link: https://bit.ly/2Xn831J

Kashif M, Kumar H, Khaja M (2016) An unusual presentation of eruptive xanthoma: a case report and literature review. Medicine 95: e4866. Link: https://bit.ly/3BQsjb2

Solak B, Kara RO, Acikgoz SB, Kosem M (2015) First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma. BMJ Case Rep bcr2015212160. Link: https://bit.ly/3BN58OG

Lee SY, Sheth CA (2019) Eruptive xanthoma associated with severe hypertriglyceridemia and poorly controlled type 1 diabetes mellitus. J Community Hosp Intern Med Perspect 9: 344-346. Link: https://bit.ly/3n6C26I

Kim WJ, Ko HC, Kim BS, Kim MB (2012) Successful treatment of xanthoma disseminatum with combined lipid lowering agents. Ann Dermatol 24: 380-382. Link: https://bit.ly/3AQG7AW

Wu NG, Guo YL, Zhu CG, Gao Y, Liu G, et al. (2019) Rapid Regression of Multiple-Site Xanthomas in an Adult with Homozygous Familial Hyperchoesterolemia by Triple Lipid-Lowering Drugs. Am J Ther 26: e775- e777. Link: https://bit.ly/3lQamUv

Peng J, Luo F, Ruan G, Peng R, Li X, et al. (2017) Hypertriglyceridemia and atherosclerosis. Lipids Health Dis 16: 233. Link: https://bit.ly/3BTTOQK

Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P (2011) Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol 57: 267-272. Link: https://bit.ly/3DHo6XE

Ridker PM, Cook NR (2013) Statins: new American guidelines for prevention of cardiovascular disease. Lancet 382: 1762-1765. Link: https://bit.ly/3aMHuGo

Hussain A, Ballantyne CM, Saeed A, Virani SS (2020) Triglycerides and ASCVD risk reduction: recent insights and future directions. Curr Atheroscler Rep 22: 25. Link: https://bit.ly/3BWsbqo

Karalis DG (2017) A review of clinical practice guidelines for the management of hypertriglyceridemia: a focus on high dose omega-3 fatty acids. Adv Ther 34: 300-323. Link: https://bit.ly/2Xppj6s

American Diabetes Association 6 (2021) Glycemic targets: standards of medical care in diabetes—2021. Diabetes Care 44: S73-84. Link: https://bit.ly/2Z3OkF4

American Diabetes Association 9 (2021) Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care 44: S111- S124. Link: https://bit.ly/3pcLHLG